Mauro P. Avanzi

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · The Lancet Oncology · 2021 · 617 citations

Medicine, Oncology, Pharmacology +13

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Mauro P. Avanzi, Oladapo Yeku, Xinghuo Li et al. · Cell Reports · 2018 · 331 citations · Full text

Medicine, Immunology, Oncology +17

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · Blood · 2020 · 107 citations

Medicine, Oncology, Pharmacology +14

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

Caron A. Jacobson, Frederick L. Locke, David B. Miklos et al. · Blood · 2018 · 68 citations

Medicine, Oncology, Pharmacology +9

Abstract CT055: Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)

Caron A. Jacobson, Jason R. Westin, David B. Miklos et al. · Cancer Research · 2020 · 61 citations

Medicine, Oncology, Pharmacology +17